Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
It is a $1.05T healthcare company. Revenue grew 49.6% over the last year, it keeps 34¢ of every dollar of sales as profit, and its net debt equals ~1.9 years of free cash flow. It trades at 41.6× earnings — in the cheapest third of its own history.
- Website
- lilly.com
- Location
- Indianapolis, IN
- Employees
- 50 000
- Sector
- Healthcare
- Founded
- 1876
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong growth, profitability and moat; Valuation lags behind.
Valuation40
- P/E vs own history13th pct · 25/25
- FCF yield1.7% · 5/25
- P/S13.9x · 5/25
- EV/EBITDA32.4x · 5/25
Growth100
- Revenue CAGR23.2% · 25/25
- Net income CAGR38.7% · 25/25
- EPS CAGR ~5Y27.6% · 25/25
- Fwd implied growth58.3% · 25/25
Profitability100
- ROIC33.4% · 25/25
- ROE92.6% · 25/25
- Net margin33.5% · 25/25
- Operating margin42.2% · 25/25
Health67
- Altman Z7.10 · 25/25
- Current ratio1.35 · 12/25
- Interest coverage29.7x · 25/25
- Net cash / debtD/A 31% · 5/25
Quality61
- Piotroski F7/9 · 22/25
- Beneish M-1.79 · 12/25
- FCF conversion68% · 15/25
- Margin stabilityσ 9.8% · 12/25
Moat80
- ROIC >12% years9/10 yrs · 25/25
- Median gross margin77.2% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst -0.9% · 5/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- FY2025FinancialRevenue crossed $50B$65.2B for the year
- FY2025FinancialBest year on record$20.6B net income
- 2023AcquisitionEli Lilly acquired Point Biopharma for $1.4 billion
- May 13, 2022ProductMounjaro / ZepboundGLP-1 franchise — the weight-loss boom makes Lilly a $1T contender
- 2018AcquisitionLilly acquired Armo Biosciences for $1.6 billion, obtaining the white blood cell-boosting cancer…
- FY2016FinancialFirst recorded profitable year$2.74B net income
- FY2016FinancialRevenue already above $10B$21.2B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- 2014AcquisitionLilly acquired Switzerland-based Novartis AG's animal health business for $5.4 billion in cash to…
- 2007AcquisitionLilly acquired Icos for $2.1 billion, after raising its offer and facing opposition from…
- 2003ProductLilly introduced Cialis (tadalafil), a competitor to Viagra for erectile dysfunction developed in a…
- 1988ProductFluoxetine (Prozac), introduced in 1988, quickly became the company's best-selling product for treatment of…
- Dec 29, 1987ProductProzacthe antidepressant that changed psychiatry
- 1955ProductLilly was the first company to mass-produce both the polio vaccine, developed in 1955 by Jonas Salk
- 1947MilestoneLilly became the first distributor of methadone in the United States and marketed it under the trade name…
- 1930ProductMerthiolate, first introduced in 1930, was an "antiseptic and germicide" that became a U.S
- 1923ProductMass-produced insulinthe first commercial insulin — saved millions
- May 10, 1876FoundedFounded by Colonel Eli Lillya Civil War veteran's pharma lab in Indianapolis
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (83.4%)
- Strongly profitable — 33.5% net margin
- Revenue growing 49.6% year over year
- Strong cash conversion — FCF is 22.8% of revenue
- Interest covered 29.7× by operating earnings
Watch-outs
- Loss-making in 1 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+49.6% YoY
- Profitable — makes more than it spends$26.7B TTM
- Profit growing — earnings are higher than last year+49.3% YoY
- Generates cash — cash left after running and investing$18.2B TTM
- Debt under control — could handle its obligations~1.9y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$1.05T market cap
- Not printing shares — share count not ballooning — you keep your slice-1.4% shares over ~5y
- Proven track record — years of profitability behind it9/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 7.1 — safe
- Pays a dividend — returns cash to shareholdersyield 0.52%
- Valuation not extreme — price not wildly above earningsP/E 41.6
Peer comparisonEli Lilly & Co. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| LLY this company | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
| AZN AstraZeneca PLC | $246.9B | 23.4 | +8.6% | 17.4% | Solid |
Head-to-head: LLY vs JNJ · LLY vs ABBV · LLY vs MRK
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/LLY
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of LLY on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $1 177.20 · market cap $1.05T.